Tuesday August 3, 12:22 pm Eastern Time
Company Press Release
Axiom Biotechnologies Inc. And Oxford Molecular
Group Complete Development Of Cell Profiling
Informatics Platform -- Profiler '99
SAN DIEGO--(BW HealthWire)--Aug. 3, 1999--Axiom Biotechnologies Inc. and Oxford
Molecular Group (LSE:OMG), announced today that they have completed co-development
of Axiom's proprietary Profiler '99 Cell BioInformatics Solution.
Profiler '99 offers a simple vehicle for integrating detailed compound registration, inventory, assay management, plate
manipulation, administration and comprehensive cell map querying features.
''The Profiler '99 takes advantage of advances Axiom has made in both cell profiling and high speed automation to rapidly
create databases of cell profiles for comprehensive secondary assay applications,'' said Pandi Veerapandian, Ph.D., Axiom's
president and chairman. ''We have been extremely pleased with Oxford Molecular's contributions to the development of
Profiler '99 as we continue to create tools for the pharmaceutical and biotechnology industry that can improve drug discovery
efficiency by leveraging cell-based assays.''
Specifically, Profiler '99 is an ORACLE 8.0.5 compatible portfolio of integrated informatics tools capable of automated data
acquisition, management and biomining, in a user-friendly data visualization environment and is designed to be compatible with
cell-based assay systems, such as Axiom's HT-PS platform. Profiler '99 leverages cell based information by offering
user-friendly visualization tools that display data sets for primary screens, potency profiles and specificity profiles, as well as
giving ready access to all experimental parameters and cell phenotype data.
Additionally, the Profiler '99 platform provides simple and complex pharmacology analyses in transparent automated formats.
These analyses include fully automated dose-response profiling, algorithmic curve-fitting comparisons, EC50 and IC50
calculations, comprehensive statistical analysis and full Schild analyses, including calculation of functional Ki and Kd values.
Profiler '99 also provides for compound searching and analyses based on functional properties of compounds on cells. All such
data can be directly exported to Oxford Molecular's DIVA or Tsar for subsequent structure-activity analyses. Exploiting such
biomining tools the scientists can come up with common pharmacophores based on functionally validated hits, to expedite the
creation of validated leads.
''Oxford Molecular is very pleased to work with Axiom to apply the OMG suite of informatics tools to create a powerful Cell
Based Bioformatics Solution,'' said Charles Nalbantian, president and COO. ''It is clear that as cell-based approaches
continue to gain importance in drug discovery such tools will be critical to taking advantage of the valuable and complex data
sets generated.''
Oxford Molecular is a leading provider of discovery and software solutions to the life sciences market. The company seeks to
deliver excellence in all its products and services and to help its customers benefit from the synergy that is created from the
integration of state-of-the-art chemistry, biology and information technology infrastructure. The Discovery Solutions Division
offers discovery research through collaboration, by providing world-class innovative technologies in chemistry and biology
which intimately match customer needs and add value to their research programs. The Software Solutions Division supplies
enterprise-wide information technology solutions for research across the entire drug discovery process. Innovative and superior
products target customer needs for excellence in each area of discovery research; and together they form integrated solutions
that add value to the flow of information through the customer's research process. The Company has its headquarters in
Oxford, England and has operations throughout the USA as well as sales offices and agents around the world.
Axiom Biotechnologies is a privately-held biotechnology company focused on improving the efficiency of drug discovery by
accelerating the process of evolving screening 'hits' to pre-clinical leads by applying an array of proprietary 'hits'-to-leads
technologies and assays. The company's patented flagship technology, the High Throughput Pharmacology System
(HT-PS(TM)), combines proprietary natural cell-based assays, high throughput automated instrumentation and novel
pharmacoinformatics and biomining tools to assess and prioritize potential lead compounds based on their functional
pharmacological properties. Through collaborations with major pharmaceutical companies, Axiom is committed to becoming
the pharmaceutical industry's partner of choice in high throughput pharmacology.
Contact:
Axiom Biotechnologies
Jim Linton, Ph.D., 619/455-4509
or
Oxford Molecular Group Inc.
Anthony D. Grass, 201/529-3323 |
